Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Bold

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Radiology Case Reports|November 8, 2019
Stroke detection with 3 different PET tracersAyca Dundar, Michael S Bold, Busranur Agac, et al.
Medicine|December 15, 2018
Arterial involvement in Erdheim-Chester disease: A retrospective cohort studyMichel Villatoro-Villar, Michael S Bold, Kenneth J Warrington, et al.
Journal of Ultrasound|July 16, 2020
Detection of distal ureteral stones in pregnancy using transvaginal ultrasoundMichael S Bold, James H Boyum, Aaron M Potretzke, et al.
The Prostate|October 11, 2021
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapyMasaya Jimbo, Jack R Andrews, Mohamed E Ahmed, et al.
The Prostate|September 12, 2022
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysisJamal Alamiri, Cameron J Britton, Mohamed E Ahmed, et al.
Clinical and Experimental Rheumatology|February 10, 2023
Relationship between histopathological features of non-infectious aortitis and the results of pre-operative 18F-FDG-PET/CT: a retrospective study of 16 patientsSimon Parreau, Olivier Espitia, Michael S Bold, et al.
Prostate Cancer and Prostatic Diseases|November 7, 2023
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancerMohamed E Ahmed, Matthew S Lee, Ahmed M Mahmoud, et al.
Haematologica|November 2, 2020
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitorYucai Wang, Kari G Rabe, Michael S Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate CancerHenan Zhang, Jacob J Orme, Feven Abraha, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Radiology Case Reports|November 8, 2019
Stroke detection with 3 different PET tracersAyca Dundar, Michael S Bold, Busranur Agac, et al.
Medicine|December 15, 2018
Arterial involvement in Erdheim-Chester disease: A retrospective cohort studyMichel Villatoro-Villar, Michael S Bold, Kenneth J Warrington, et al.
Journal of Ultrasound|July 16, 2020
Detection of distal ureteral stones in pregnancy using transvaginal ultrasoundMichael S Bold, James H Boyum, Aaron M Potretzke, et al.
The Prostate|October 11, 2021
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapyMasaya Jimbo, Jack R Andrews, Mohamed E Ahmed, et al.
The Prostate|September 12, 2022
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysisJamal Alamiri, Cameron J Britton, Mohamed E Ahmed, et al.
Clinical and Experimental Rheumatology|February 10, 2023
Relationship between histopathological features of non-infectious aortitis and the results of pre-operative 18F-FDG-PET/CT: a retrospective study of 16 patientsSimon Parreau, Olivier Espitia, Michael S Bold, et al.
Prostate Cancer and Prostatic Diseases|November 7, 2023
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancerMohamed E Ahmed, Matthew S Lee, Ahmed M Mahmoud, et al.
Haematologica|November 2, 2020
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitorYucai Wang, Kari G Rabe, Michael S Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate CancerHenan Zhang, Jacob J Orme, Feven Abraha, et al.
Pageof 1